A recent study published in the New England Journal of Medicine examined the efficacy of two new weight-loss drugs, Wegovy and Zepbound. In a trial involving 751 participants, Zepbound demonstrated a greater weight loss, with users shedding 20.2% of their initial weight, compared to 13.7% for Wegovy users. Additionally, waist circumference reductions were greater in the Zepbound group. Both medications presented similar gastrointestinal side effects; however, Zepbound had more injection-site reactions initially but these diminished over time, suggesting they become more tolerable with use.
The results showed that patients using Zepbound lost 20.2% of their initial body weight, significantly more than those using Wegovy, who lost 13.7%.
Zepbound users lost an average of 18.4 cm from their waist circumference, whereas Wegovy users lost 13.0 cm, elucidating Zepbound's superior effectiveness.
While both drugs had similar gastrointestinal side effects, Zepbound users reported more injection-site reactions, which tended to decrease over time with continued use.
Dr. Leonard Glass emphasized the necessity of having diverse treatment options for patients, highlighting that these emerging therapies are crucial improvements over previous weight-loss options.
Collection
[
|
...
]